Plus Therapeutics Secures AMA PLA Code for CNSide Test, Boosting U.S. Commercial Rollout
Event summary
- Plus Therapeutics received a new Proprietary Laboratory Analyses (PLA) CPT code (0640U) for its CNSide® CSF Tumor Cell Enumeration test, effective July 1, 2026.
- The dedicated billing code simplifies reimbursement processes and supports broader clinical adoption for managing leptomeningeal metastases.
- CNSide Diagnostics, a subsidiary, focuses on detecting tumor cells in cerebrospinal fluid for advanced cancer patients.
- The coding milestone strengthens the reimbursement infrastructure for the ongoing U.S. commercial launch of the CNSide test.
The big picture
The AMA PLA code approval for CNSide marks a critical step in streamlining reimbursement and accelerating commercial adoption. This aligns with broader industry trends toward precision diagnostics for CNS cancers, where early detection and targeted treatments are increasingly prioritized. The coding milestone supports Plus Therapeutics' strategy to build CNSide into a sustainable commercial franchise, complementing its therapeutic pipeline.
What we're watching
- Reimbursement Dynamics
- How the new PLA code will affect payer coverage and adoption rates for the CNSide test.
- Clinical Adoption
- Whether oncologists and neurologists will increasingly integrate the CNSide test into standard care protocols.
- Revenue Growth
- The pace at which the diagnostics business will scale alongside Plus Therapeutics' therapeutic pipeline.
Related topics